MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Autosomal dominant Parkinson’s disease caused by SNCA p.E46K variant in family with Russian ancestry: A case report

    K. Senkevich, I. Miliukhina, A. Zhuravlev, M. Shumilova, M. Beletskaia, A. Tyurin, M. Grunina, A. Rybakov, J. Ahmad, F. Asayesh, A. Timofeeva, Z. Gan-Or, A. Emelyanov, S. Pchelina (Montreal, Canada)

    Objective: To report a family with autosomal dominant Parkinson’s disease (PD) with SNCA p.E46K variant. Background: Alpha-synuclein, encoded by SNCA, is a part of Lewy…
  • 2023 International Congress

    Parkinson’s Team Training is beneficial for new and established PD Centers

    E. Pollard, K. Lyons, D. Beran, C. Hunter, H. Cianci, E. Book (New York, USA)

    Objective: To determine if the Parkinson’s Foundation (PF) Parkinson’s disease (PD) Team Training (TT) empowers Parkinson’s interprofessional healthcare teams to make changes in their care…
  • 2023 International Congress

    Distinct deep grey matter iron accumulation in tremoric syndromes; an apparent quantitative susceptibility mapping mangetic resonance study

    A. Martín-Bastida, I. Aviles-Olmos, A. Gorospe-Osinalde, V. Suarez-Vega, P. Dominguez-Echavarri, R. García-Eulate, C. Sánchez-Catasús, MC. Rodríguez-Oroz (Pamplona, Spain)

    Objective: To investigate regional iron accumulation in patients with essential tremor (ET) and Parkinson´s disease (PD) and its clinical associations with apparent susceptibility-weighted imaging (SWI)…
  • 2023 International Congress

    Emergent alpha-beta oscillations are accompanied with worsening motor symptoms in Parkinson’s disease

    E. Belova, U. Semenova, A. Gamaleya, A. Tomskiy, A. Sedov (Moscow, Russian Federation)

    Objective: The aim of the study was to imply observer-independent approach to search for the ranges of stable oscillations in broad alpha-beta range inside the…
  • 2023 International Congress

    The efficacy of dopamine agonists or monoamine oxidase type B inhibitors as monotherapy in patients with early Parkinson disease: A network meta-analysis

    CSC. Chuang (Changhua, Taiwan)

    Objective: This study aimed to investigate the effectiveness of dopamine agonists or monoamine oxidase type B inhibitors (MAOB-I) as monotherapy in patients with early Parkinson's…
  • 2023 International Congress

    15-year effects of initiating treatment for Parkinson’s disease with dopamine agonists or monoamine oxidase B inhibitors compared with levodopa: final results of PD MED early disease randomisation

    C. Clarke, C. Rick, S. Patel, R. Wooley, N. Rowland, J. Futterer, R. Ottridge, C. Jenkinson, R. Gray (Birmingham, United Kingdom)

    Objective: PD MED EARLY is a large, pragmatic trial aiming to determine which class of drug as initial treatment provides the most effective long-term control…
  • 2023 International Congress

    An Exploration of the Psychosocial Impact of Receiving Treatment at a Sialorrhea Clinic for People with Parkinson’s Disease

    M. Vazirian Zadeh, J. Adenwalla, C. Marquis, B. Mohamed, C. Thomas, R. Lewis-Morton (Penarth, United Kingdom)

    Objective: To explore the psychosocial impact (impact on quality of life, self-compassion, self-esteem & shame) of receiving treatment for sialorrhea in people with Parkinson’s. Background:…
  • 2023 International Congress

    Bone Health in Parkinson’s Disease

    E. Killeen, C. Gallagher, A. Mcdonough (Dublin, Ireland)

    Objective: Optimise bone health in people with Parkinson’s Disease Background: People with Parkinson’s Disease (PD) have an increased risk of osteoporosis and associated fractures due…
  • 2023 International Congress

    Randomized Controlled Trial comparing continuous intrajejunal levodopa infusion and deep brain stimulation for Parkinson’s disease. Cost-effectiveness and cost-utility outcomes of the INVEST study

    D. van Poppelen, M. van Barreveld, R. de Bie, P. Schuurman, F. van Delft, G. Geurtsen, R. de Haan, M. Dijkgraaf, J. Dijk (Amsterdam, Netherlands)

    Objective: To determine the costs of continuous intrajejunal levodopa infusion (CILI) and deep brain stimulation (DBS) for Parkinson’s disease (PD), and to study the cost-effectiveness…
  • 2022 International Congress

    A prospective, controlled study of subthalamic stimulation in Parkinson’s disease: quality of life outcome at the 5-year follow-up

    S. Jost, S. Aloui, A. Rizos, K. Ashkan, J. Evans, A. Sauerbier, J. Petry-Schmelzer, A. Gronostay, G. Fink, M. Barbe, V. Visser-Vandewalle, A. Antonini, M. Silverdale, P. Martinez-Martin, L. Timmermann, K. Ray Chaudhuri, H. Dafsari (Cologne, Germany)

    Objective: To compare the 60-months quality of life (QoL) effects of subthalamic stimulation (STN-DBS) to standard-of-care oral/transdermal medical therapy (MED) in Parkinson's disease (PD). Background:…
  • « Previous Page
  • 1
  • …
  • 190
  • 191
  • 192
  • 193
  • 194
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley